Synthesis of new cotelomers derived from tris(hydroxymethyl) aminomethane bearing arabinofuranosylcytosine moieties. Preliminary results on their in vitro and in vivo antitumoral activities
摘要:
As an approach to the development of drug delivery systems, a new class of low macromolecular carriers called telomers bearing both antitumor agent such as arabinofuranosylcytosine (Ara-C) and galactose moieties were synthesized. These compounds were prepared by telomerization of tris(hydroxymethyl) acrylamidomethane (THAM) or monogalactosylated THAM and Ara-C polymerizable derivatives in the presence of transfer reagent such as alkanethiol or perfluoroalkanethiol. Their antitumor activities were assessed both in vitro and in vivo against a mouse cell Line, murine B16 melanoma. The biological results show that the cytotoxic effect of Ara-C is preserved in vitro and in vivo when the drug is grafted to the telomeric structure. (C) Elsevier, Paris.
Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK)
作者:Tiancheng Fu、Yingying Zuo、Zhenpeng Zhong、Xuan Chen、Zhengying Pan
DOI:10.1016/j.ejmech.2021.114051
日期:2022.2
understood. Herein, we present the discovery of a novel series of selective and irreversibleinhibitors of BLK with nanomolar potency against BLK in biochemical and cellular assays. Compound 25 demonstrated potent antiproliferative activities against several B cell lymphoma cell lines. These compounds constitute the first series of selectiveinhibitors developed for BLK and could help expedite the exploration
B 淋巴酪氨酸激酶 (BLK) 是 SRC 家族非受体酪氨酸激酶的成员,参与 B 细胞受体 (BCR) 信号通路和 B 细胞发育和功能。BLK 的失调与自身免疫性疾病和癌症有关。然而,缺乏用于 BLK 的良好工具化合物,并且对 BLK 介导生理和病理过程的分子机制知之甚少。在此,我们展示了一系列新型选择性和不可逆 BLK 抑制剂的发现,这些抑制剂在生化和细胞分析中具有纳摩尔级的 BLK 效力。化合物25证明了对几种 B 细胞淋巴瘤细胞系的有效抗增殖活性。这些化合物构成了为 BLK 开发的第一批选择性抑制剂,有助于加快 BLK 功能的探索。
Water soluble polymers containing amino acid residues for dental
申请人:The Ohio State University
公开号:US05369142A1
公开(公告)日:1994-11-29
Glass ionomer cements for dental restoratives with improved physical properties are produced by the present invention. Acryloyl and methacryloyl derivatives of amino acids are used in the invention to copolymerize with acrylic acid, methacrylic acid or various acrylic acid-comonomer mixtures to produce water soluble polycarboxylic acids.
An alternative medicinal chemistry approach was conducted on Bruton’styrosinekinase (BTK) inhibitor 1 (ibrutinib) by merging the pyrazolo[3,4-d]pyrimidine component into a tricyclic skeleton. Two types of compounds were prepared, and their biochemical activities on BTK as well as stereochemistry effects were determined. Structural optimization focusing on the reactive binding group to BTK Cys481
通过将吡唑并[3,4- d ]嘧啶组分合并成三环骨架,对布鲁顿酪氨酸激酶(BTK)抑制剂1(依鲁替尼)进行了另一种药物化学处理。制备了两种类型的化合物,并确定了它们对BTK的生化活性以及立体化学作用。进行了结构优化,重点是与BTK Cys481的反应性结合基团和以代谢研究为指导的代谢位点。7S被认为是最有效的,对BTK的IC 50值为0.4 nM,对BTK依赖的TMD8细胞的IC 50为16 nM。相比1,7S对B细胞受体信号通路的抑制作用强一些。在源自TMD8细胞的动物异种移植模型中,7S在15 mg / kg QD剂量下显示出5.3的相对肿瘤体积,在25 mg / kg QD较高剂量下比1(RTV 6.6)更有效。所有这些结果表明7S是一种值得进一步分析的新型BTK抑制剂。
[EN] MULTIFOCAL CONTACT LENS DISPLAYING IMPROVED VISION ATTRIBUTES<br/>[FR] LENTILLE DE CONTACT MULTIFOCALE PRÉSENTANT DES ATTRIBUTS DE VISION AMÉLIORÉS
申请人:JOHNSON & JOHNSON VISION CARE
公开号:WO2021038369A1
公开(公告)日:2021-03-04
Described are multifocal contact lenses that contain high energy visible (HEV) light absorbing compounds and their use for improving one or more vision attributes.
Forty-one new focal adhesion kinase (FAK) covalentinhibitors were designed and synthesized based on FAK inhibitor TAE226. Compound 11w displayed the highest inhibition of FAK with an IC50 value of 35 nM and exhibited potent anticancer activity against Hela, HCT116 and MDA-MB-231 cell lines with IC50 values of 0.41, 0.01 and 0.11 μM respectively, compared to TAE226 (2.68, 0.64 and 4.19 μM respectively)